Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Next Previous
Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMISE 1
  • Sponsors Alder Biopharmaceuticals

Most Recent Events

  • 27 Apr 2023 Results from PROMISE-1 and PROMISE-2 ; demonstrating the lack of a wearing off effect with eptinezumab in preventive migraine treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 10 Dec 2022 Results of a post-hoc analysis from two clinical studies (PROMISE-1 and PROMISE-2) assessing proportions of patients shifting from higher to lower levels of headache frequency over Months 1-6 of treatment presented at the 16th European headache federation COngress
  • 12 Jun 2022 Results of a post-hoc analysis assessing proportions of patients shifting from higher levels of headache/migraine frequency to lower levels over the first 6 months of treatment.from two clinical studies: PROMISE-1 and PROMISE-2 presented at the 64th Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top